Sunday, November 13, 2022 2:39:55 PM
Happy: about “loopholes.” I get your point and to you and a whole lot of shareholders including ME yes it seems like management is using the (presumed) embargo as a convenient -maybe even flexible - excuse to avoid disclosure. And your further point about how management seems willing to interpret and apply those rules to follow a course of action or silence that we might prefer that they not follow. That’s not grounds for criticism that’s grounds for commendation for skillful course charting in changing conditions.
When I go to my tax lawyer I don’t want
him to follow the most superficial interpretation of the code. I want him to squeeze out every favorable, reasonable provision or interpretation and maybe some that are even marginal as long as I know the balance and make the decision. If otherwise he’s not doing his job. I expect absolutely no less from management assuming (as it appears) that management has determined in their exercise of fiduciary judgment that this is the best course of action for the company.
So, respectfully, I draw the exact opposite conclusion than you do about the careful application of “rules.” Best wishes.
PS my personal tax return w state returns was 187 pages this year. For perspective
When I go to my tax lawyer I don’t want
him to follow the most superficial interpretation of the code. I want him to squeeze out every favorable, reasonable provision or interpretation and maybe some that are even marginal as long as I know the balance and make the decision. If otherwise he’s not doing his job. I expect absolutely no less from management assuming (as it appears) that management has determined in their exercise of fiduciary judgment that this is the best course of action for the company.
So, respectfully, I draw the exact opposite conclusion than you do about the careful application of “rules.” Best wishes.
PS my personal tax return w state returns was 187 pages this year. For perspective
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
